Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthracycline-taxane versus anthracycline-taxane plus carboplatin as (neo)adjuvant therapy in triple-negative breast cancer
KCT0003529Phase 3Active, not recruiting
- Sponsor
- GC Biopharma
- Start
- Dec 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by GC Biopharma. Started Dec 2015; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0003529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003529.